AACR 2026 | Abbisko Therapeutics Showcases Six Research Advances Highlighting pan-KRAS, 4th Generation EGFR, and Synthetic Lethality Approaches

Abbisko Therapeutics (HKEX: 02256) announced that the company presented six latest preclinical and translational research ...
Nature

New drugs take aim at one of cancer’s deadliest mutations

Armed with sophisticated chemistry and fresh approaches to drug design, researchers are closing in on innovative strategies to undermine a cancer-causing mutant protein once considered ‘undruggable’.
The New Yorker

We Are All Constantly Mutating—and That’s a Good Thing

As I am writing this, my DNA is changing. And, as you read this, so is yours. People tend to assume that the genes we inherit from our parents are a fixed blueprint for our growth and development, ...
BioSpace

Abbisko Therapeutics’ FGFR4 Inhibitor Irpagratinib Granted Orphan Drug Designation by EMA for Hepatocellular Carcinoma

SHANGHAI, March 31, 2026 /PRNewswire/ -- 31 March 2026, Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256) announced that its independently developed, highly selective ...
Game Rant

Monster Hunter Stories 3 Mutation List

Krista McCay is a writer specializing in video game guides and walkthroughs. She first entered the industry in 2022 while studying English at UC Santa Barbara and working part-time as an editor. It ...
Targeted Oncology

FDA Grants Lirafugratinib Priority Review in FGFR2-Altered Cholangiocarcinoma

The oral FGFR2 inhibitor lirafugratinib is being reviewed by the FDA for the second-line treatment of cholangiocarcinoma harboring FGFR2 alternations. The FDA has granted a priority review to a new ...